Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 10 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT06981806Phase 1
• Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsRecruitingNCT06981325Phase 2
• SSGJ-707 in Advanced Non-Small Cell Lung CancerRecruitingNCT06980272Phase 3
• XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid LeukemiaRecruitingNCT06980155Early Phase 1
• Ivonescimab for the Treatment of Thymic CancerRecruitingNCT06980077Phase 2
• A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
• Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast CancerNot yet recruitingNCT06977542Phase 2
• PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCRecruitingNCT06977074Phase 2
• A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingNCT06976190Phase 3
• A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
• QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerRecruitingNCT06967103Phase 2
• The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ ECNot yet recruitingNCT06965829Phase 2
• Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast CancerRecruitingNCT06964906Phase 2
• CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCRecruitingNCT06964568Phase 3
• Saci Nivo Rela for TNBCRecruitingNCT06963905Phase 1/2
• Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingNCT06963346Phase 1
• A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingNCT06962787Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT06959693Phase 2/3
• Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerRecruitingNCT06959550Phase 2
• Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of RecurrenceNot yet recruitingNCT06958484Phase 2
• Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06956716Phase 1/2
• Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingNCT06954480Phase 2
• JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Phase 2
• Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruitingNCT06954116Phase 2
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsRecruitingNCT06953089Phase 2
• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 3
• A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsRecruitingNCT06952010Phase 1
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
• Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT06951841Phase 4
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Phase 2
• AK112 and Chemotherapy in First-line Metastatic Colorectal CancerRecruitingNCT06951503Phase 3
• Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung CancerNot yet recruitingNCT06951399Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingNCT06949761Phase 1/2
• Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）RecruitingNCT06949111Phase 2
• A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple MetastasesRecruitingNCT06947694Phase 2
• Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNot yet recruitingNCT06946836Phase 2
• A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
• A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic CancerRecruitingNCT06944106Phase 2
• AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
• Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruitingNCT06942767Phase 2
• NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2
• Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic TumorsRecruitingNCT06941766Phase 1/2
• Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT06940518Phase 2
• IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)RecruitingNCT06940440Phase 1
• Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.RecruitingNCT06940388Phase 2
• Toripalimab With Chemotherapy for Sinus CancerRecruitingNCT06940180Phase 2
• QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaRecruitingNCT06939855Phase 2
• Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsRecruitingNCT06938880Phase 1/2
• A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerRecruitingNCT06938321Phase 1/2
• ONO-4538 Study in Patients With Richter's TransformationRecruitingNCT06936943Phase 2
• A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C MutationNot yet recruitingNCT06936644Phase 2
• A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal CancerEnrolling by invitationNCT06936488Not applicable
• Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4
• Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ AdenocarcinomaRecruitingNCT06932068Phase 2
• Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon CancerEnrolling by invitationNCT06931808Phase 4
• A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyRecruitingNCT06931717Phase 3
• Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentEnrolling by invitationNCT06931613Phase 2
• Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06931145Phase 4
• A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence RiskRecruitingNCT06930573Phase 4
• Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal CancerRecruitingNCT06928584Phase 2
• Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Phase 2
• A Study of Ivonescimab in People With Endometrial and Cervical CancersRecruitingNCT06925724Phase 2
• SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCNot yet recruitingNCT06925048Phase 2
• Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal CholangiocarcinomaRecruitingNCT06923475Phase 2/3
• Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingNCT06921785Phase 3
• Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingNCT06918132Phase 2
• PALACE: Cemiplimab Trial According to ctDNA LevelsRecruitingNCT06917573Phase 2
• Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT06916975Phase 2
• Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder CancerRecruitingNCT06916494Phase 1
• Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerRecruitingNCT06914440Phase 2
• TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd ECRecruitingNCT06914297Phase 2
• Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction TherapyNot yet recruitingNCT06914050Phase 2
• Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06914011Phase 3
• TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingNCT06912711Phase 2
• Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
• A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsRecruitingNCT06911827Phase 1/2
• Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruitingNCT06911255Phase 1/2
• Neoadjuvant QL1706 Therapy for ESCCRecruitingNCT06908382Phase 2
• A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCRecruitingNCT06908304Phase 3
• Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ CancerNot yet recruitingNCT06904300Phase 2
• Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Phase 2
• Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)Not yet recruitingNCT06903871Phase 2
• Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerRecruitingNCT06903858Phase 2
• Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT06903377Phase 1/2
• Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaNot yet recruitingNCT06903273Phase 2
• ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung CancerRecruitingNCT06902272Phase 2
• Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDSNot yet recruitingNCT06902038Not applicable
• Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
• Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaRecruitingNCT06898970Phase 2
• A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Not yet recruitingNCT06897527Phase 4
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCRecruitingNCT06897046Phase 2
• 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)RecruitingNCT06896188Phase 1
• Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaEnrolling by invitationNCT06896110Phase 1
• The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCCNot yet recruitingNCT06895369Phase 2
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
• Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable

← Immune Checkpoint Inhibitors overview